EFMH
COGT icon

E Fund Management (HK)’s Cogent Biosciences COGT Stock Holding History

E Fund Management (HK)’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3K Buy
524
+135
+35% +$4.72K 0.01% 314
2026
Q1 		$15K Buy
+389
New +$14.4K 0.01% 251

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management (HK)'s COGT Position: Q2 2026 in Review

E Fund Management (HK) increased its Cogent Biosciences (COGT) stake by 35% in Q2 2026, buying an estimated $4.72K and bringing the position to 524 shares worth $20.3K. The position accounts for 0.01% of the portfolio, ranked #314.

E Fund Management (HK) first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • E Fund Management (HK) held 524 shares of Cogent Biosciences worth $20.3K as of Q2 2026.
  • E Fund Management (HK) bought 135 Cogent Biosciences shares in Q2 2026, an estimated $4.72K.
  • Cogent Biosciences made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #314 holding.
  • E Fund Management (HK) first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.